Theralogix报告记录了2025年的增长、领导力的改变以及2026年新的科学支持的补充发射。 Theralogix reports record 2025 growth, leadership changes, and new science-backed supplement launches for 2026.

以马里兰为基地的一家补充公司Theralogix报告说,2025年成绩创纪录,收入和利润增长25%,23年来表现最强劲。 Theralogix, a Maryland-based supplement company, reported record 2025 results with 25% growth in revenue and profit, its strongest performance in 23 years. 创始的CEO Jay Hammer 即将下台成为CEO 荣誉首席执行官,由Eyepromise/ZeaVision的前CEO Andreas Wolf接替。 Founding CEO Jay Hammer is stepping down to become CEO Emeritus, succeeded by Andreas Wolf, former CEO of EyePromise/ZeaVision. 克里斯托弗·古德 超过15年的COO 晋升为总统 Christopher Good, COO for over 15 years, is promoted to President. 该公司计划在2026-OvaNAD+TM、AgeRxTM、Tre BiomeTM和AndrosynTM推出新产品,重点是生殖健康、长寿、直肠健康和睾酮支持。 The company plans to launch new products in 2026—OvaNAD+™, AgeRx™, TreBiome™, and Androsyn™—focused on reproductive health, longevity, gut health, and testosterone support. Theralogix继续强调科学支持的配方、NSF国际的第三方测试以及医生的建议。 Theralogix continues to emphasize science-backed formulations, third-party testing by NSF® International, and physician recommendations.